RASSF1 and melanoma: The percentage of cases with methylated RASSF1A promoter in cfDNA was higher respectively in in situ (8/14, 57%), invasive (24/60, 40%), and metastatic (7/10, 70%) melanoma patients than in controls (Pearson chi-squared test, p < 0.001).